A Study of Stereotactic Body Radiation Therapy Guided by MRI in People with Colorectal Cancer That Spread to the Liver


Full Title

Ablative Dose Single Fraction MRguided Colorectal Liver Metastasis SBRT


Researchers want to see if a single radiation therapy dose can limit the growth of colorectal cancer liver metastases. The people in this study have colorectal cancer that has metastasized (spread) to the liver. The treatment is called high-dose stereotactic body radiation therapy (SBRT).

SBRT precisely delivers radiation to tumors using imaging scans. The SBRT in this study is delivered using magnetic resonance imaging (MRI). The machines used to give this treatment are called MR linear accelerators. They can be used to adjust the treatment plan on the spot to deliver radiation even more precisely.

If you join this study, you will have one session of high-dose SBRT guided by MRI. You will also have a contrast agent called gadoxetic acid. It is routinely used for MRI scans of the liver. The contrast makes it easier to find liver tumors.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have 1 to 3 colorectal cancer metastases in the liver.
  • Have finished any prior chemotherapy to the liver arteries at least 2 weeks before getting the study therapy.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Marsha Reyngold’s office at 516-559-1527.




Phase II (phase 2)



Neelam Tyagi

ClinicalTrials.gov ID